1516 related articles for article (PubMed ID: 26181180)
1. The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ.
Coromilas EJ; Wright JD; Huang Y; Feldman S; Neugut AI; Chen L; Hershman DL
JAMA Oncol; 2015 Jun; 1(3):323-32. PubMed ID: 26181180
[TBL] [Abstract][Full Text] [Related]
2. The use of sentinel lymph node biopsy in the treatment of breast ductal carcinoma in situ: A Danish population-based study.
Holm-Rasmussen EV; Jensen MB; Balslev E; Kroman N; Tvedskov TF
Eur J Cancer; 2017 Dec; 87():1-9. PubMed ID: 29096155
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Surgical Trends for Axillary Lymph Node Management in Patients with Ductal Carcinoma In Situ Using the NSQIP Database: Are We Following National Guidelines?
Pyfer BJ; Jonczyk M; Jean J; Graham RA; Chen L; Chatterjee A
Ann Surg Oncol; 2020 Sep; 27(9):3448-3455. PubMed ID: 32232706
[TBL] [Abstract][Full Text] [Related]
4. Trends and clinicopathological predictors of axillary evaluation in ductal carcinoma in situ patients treated with breast-conserving therapy.
Huang NS; Si J; Yang BL; Quan CL; Chen JJ; Wu J
Cancer Med; 2018 Jan; 7(1):56-63. PubMed ID: 29271113
[TBL] [Abstract][Full Text] [Related]
5. Axillary evaluation and lymphedema in women with ductal carcinoma in situ.
Coromilas EJ; Wright JD; Huang Y; Feldman S; Neugut AI; Hillyer GC; Chen L; Hershman DL
Breast Cancer Res Treat; 2016 Jul; 158(2):373-84. PubMed ID: 27365080
[TBL] [Abstract][Full Text] [Related]
6. Predictors of treatment with mastectomy, use of sentinel lymph node biopsy and upstaging to invasive cancer in patients diagnosed with breast ductal carcinoma in situ (DCIS) on core biopsy.
Chin-Lenn L; Mack LA; Temple W; Cherniak W; Quinn RR; Ravani P; Lewin AM; Quan ML
Ann Surg Oncol; 2014 Jan; 21(1):66-73. PubMed ID: 24046105
[TBL] [Abstract][Full Text] [Related]
7. Time trends and inter-hospital variation in treatment and axillary staging of patients with ductal carcinoma in situ of the breast in the era of screening in Southern Netherlands.
van Steenbergen LN; Voogd AC; Roukema JA; Louwman WJ; Duijm LE; Coebergh JW; van de Poll-Franse LV
Breast; 2014 Feb; 23(1):63-8. PubMed ID: 24291376
[TBL] [Abstract][Full Text] [Related]
8. Ductal carcinoma in situ: value of sentinel lymph node biopsy.
Sakr R; Barranger E; Antoine M; Prugnolle H; Daraï E; Uzan S
J Surg Oncol; 2006 Oct; 94(5):426-30. PubMed ID: 16967457
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with lymph node assessment in ductal carcinoma in situ: analysis of 1988-2002 seer data.
Porembka MR; Abraham RL; Sefko JA; Deshpande AD; Jeffe DB; Margenthaler JA
Ann Surg Oncol; 2008 Oct; 15(10):2709-19. PubMed ID: 18483831
[TBL] [Abstract][Full Text] [Related]
10. The State of Surgical Axillary Management and Adjuvant Radiotherapy for Early-stage Invasive Breast Cancer in the Modern Era.
Mann JM; Wu X; Christos P; Nagar H
Clin Breast Cancer; 2018 Aug; 18(4):e477-e493. PubMed ID: 29031423
[TBL] [Abstract][Full Text] [Related]
11. Utilization of Axillary Surgery for Patients With Ductal Carcinoma In Situ: A Report From the National Cancer Data Base.
Miller ME; Kyrillos A; Yao K; Kantor O; Tseng J; Winchester DJ; Shulman LN
Ann Surg Oncol; 2016 Oct; 23(10):3337-46. PubMed ID: 27334212
[TBL] [Abstract][Full Text] [Related]
12. The Role of Sentinel Lymph Node Biopsy and Factors Associated with Invasion in Extensive DCIS of the Breast Treated by Mastectomy: The Cinnamome Prospective Multicenter Study.
Tunon-de-Lara C; Chauvet MP; Baranzelli MC; Baron M; Piquenot J; Le-Bouédec G; Penault-Llorca F; Garbay JR; Blanchot J; Mollard J; Maisongrosse V; Mathoulin-Pélissier S; MacGrogan G
Ann Surg Oncol; 2015 Nov; 22(12):3853-60. PubMed ID: 25777085
[TBL] [Abstract][Full Text] [Related]
13. Is Sentinel Lymph Node Biopsy Indicated at Completion Mastectomy for Ductal Carcinoma In Situ?
Pilewskie M; Karsten M; Radosa J; Eaton A; King TA
Ann Surg Oncol; 2016 Jul; 23(7):2229-34. PubMed ID: 26960927
[TBL] [Abstract][Full Text] [Related]
14. Use of Axillary Staging in the Management of Ductal Carcinoma In Situ.
Van Zee KJ
JAMA Oncol; 2015 Jun; 1(3):332-3. PubMed ID: 26181181
[No Abstract] [Full Text] [Related]
15. [A single-center retrospective study on axillary evaluation in 1 557 breast ductal carcinoma in situ patients between 2006 and 2016].
Si J; Quan CL; Mo M; Guo R; Su YH; Yang BL; Chen JJ; Shao ZM; Wu J
Zhonghua Wai Ke Za Zhi; 2019 Sep; 57(9):681-685. PubMed ID: 31474060
[No Abstract] [Full Text] [Related]
16. Necessity of sentinel lymph node biopsy in ductal carcinoma in situ patients: a retrospective analysis.
Shin YD; Lee HM; Choi YJ
BMC Surg; 2021 Mar; 21(1):159. PubMed ID: 33752671
[TBL] [Abstract][Full Text] [Related]
17. Variations in the management of the axilla in screen-detected ductal carcinoma in situ: evidence from the UK NHS breast screening programme audit of screen detected DCIS.
Nicholson S; Hanby A; Clements K; Kearins O; Lawrence G; Dodwell D; Bishop H; Thompson A;
Eur J Surg Oncol; 2015 Jan; 41(1):86-93. PubMed ID: 25441934
[TBL] [Abstract][Full Text] [Related]
18. Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy.
van Roozendaal LM; Goorts B; Klinkert M; Keymeulen KBMI; De Vries B; Strobbe LJA; Wauters CAP; van Riet YE; Degreef E; Rutgers EJT; Wesseling J; Smidt ML
Breast Cancer Res Treat; 2016 Apr; 156(3):517-525. PubMed ID: 27083179
[TBL] [Abstract][Full Text] [Related]
19. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.
Schulze T; Mucke J; Markwardt J; Schlag PM; Bembenek A
J Surg Oncol; 2006 Feb; 93(2):109-19. PubMed ID: 16425290
[TBL] [Abstract][Full Text] [Related]
20. DCIS and axillary nodal evaluation: compliance with national guidelines.
Mitchell KB; Lin H; Shen Y; Colfry A; Kuerer H; Shaitelman SF; Babiera GV; Bedrosian I
BMC Surg; 2017 Feb; 17(1):12. PubMed ID: 28173790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
